These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 9589247)

  • 41. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
    Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
    Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of short term continuous subcutaneous insulin lispro versus continuous intravenous regular insulin in poorly controlled, hospitalized, type 2 diabetic patients.
    Boullu-Sanchis S; Ortega F; Chabrier G; Busch MS; Uhl C; Pinget M; Jeandidier N
    Diabetes Metab; 2006 Sep; 32(4):350-7. PubMed ID: 16977263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
    DeFelippis MR; Bell MA; Heyob JA; Storms SM
    Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.
    Mohn A; Matyka KA; Harris DA; Ross KM; Edge JA; Dunger DB
    Diabetes Care; 1999 Jan; 22(1):27-32. PubMed ID: 10333899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients.
    Guerci B; Benichou M; Floriot M; Bohme P; Fougnot S; Franck P; Drouin P
    Diabetes Care; 2003 Apr; 26(4):1137-41. PubMed ID: 12663586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.
    Castillo MJ; Scheen AJ; Lefèbvre PJ
    J Clin Endocrinol Metab; 1996 May; 81(5):1975-8. PubMed ID: 8626867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
    Rave K; Heise T; Pfützner A; Heinemann L; Sawicki PT
    Diabetes Care; 2001 May; 24(5):886-90. PubMed ID: 11347749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
    Clin Ther; 1997; 19(1):62-72. PubMed ID: 9083709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
    Bode BW; Garg SK; Norwood P; Morales C; Hardy T; Liu R; Ignaut D
    Diabetes Technol Ther; 2021 Jan; 23(1):41-50. PubMed ID: 32640842
    [No Abstract]   [Full Text] [Related]  

  • 53. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.
    Deeb LC; Holcombe JH; Brunelle R; Zalani S; Brink S; Jenner M; Kitson H; Perlman K; Spencer M
    Pediatrics; 2001 Nov; 108(5):1175-9. PubMed ID: 11694699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Koivisto VA; Pfützner A; Trautmann ME; Vignati L; DiMarchi R
    Diabetes; 1997 Feb; 46(2):265-70. PubMed ID: 9000704
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness.
    Radermecker RP; Scheen AJ
    Diabetes Metab Res Rev; 2004; 20(3):178-88. PubMed ID: 15133748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study.
    Catargi B; Meyer L; Melki V; Renard E; Jeandidier N;
    Diabetes Metab; 2002 Apr; 28(2):133-7. PubMed ID: 11976565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin.
    Tokuyama Y; Nozaki O; Kanatsuka A
    Diabetes Res Clin Pract; 2001 Dec; 54(3):209-12. PubMed ID: 11689276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [How should we use the short-acting insulin analog Lys-Pro in external continuous subcutaneous pumps?].
    Guerci B; Jeandidier N; Lassmann-Vague V; Renard E; Hanaire-Broutin H
    Diabetes Metab; 2000 Dec; 26(6):513-9. PubMed ID: 11173725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
    Homko C; Deluzio A; Jimenez C; Kolaczynski JW; Boden G
    Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.
    Ebeling P; Jansson PA; Smith U; Lalli C; Bolli GB; Koivisto VA
    Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.